User:Mr. Ibrahem/Nintedanib

Mr. Ibrahem/Nintedanib
	Nintedanib
Clinical data
Trade names	Vargatef, Ofev
Other names	Nintedanib esylate, BIBF 1120
AHFS/Drugs.com	Monograph
MedlinePlus	a615009
License data	EU EMA: by INN; US DailyMed: Nintedanib; US FDA: Nintedanib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Tyrosine-kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	4.7%
Protein binding	97.8%
Metabolism	Esterases, glucuronidation
Elimination half-life	10–15 hrs
Excretion	93% via faeces
Identifiers
	IUPAC name Methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate;
Chemical and physical data
Formula	C31H33N5O4
Molar mass	539.636 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N/C(=C\3/C4=C(C=C(C=C4)C(=O)OC)NC3=O)/C5=CC=CC=C5;
	InChI InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-; Key:XZXHXSATPCNXJR-ZIADKAODSA-N;
	(what is this?) (verify)

Nintedanib, sold under the brand names Ofev and Vargatef, is a medication used to treat idiopathic pulmonary fibrosis and a type of non-small-cell lung cancer (NSCLC).^[2]^[4] It is specifically used for adenocarcinoma NSCLC that is advanced.^[2] It is taken by mouth.^[2]

Common side effects include abdominal pain, vomiting, liver inflammation, headache, and diarrhea.^[4] Other side effects may include blood clots, bleeding, aneurysm, and gastrointestinal perforation.^[4]^[5] Use during pregnancy may harm the baby.^[4] It is a tyrosine-kinase inhibitor which blocks vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet derived growth factor (PDGF).^[2]

Nintedanib was approved for medical use in the United States and Europe in 2014.^[4]^[2] In the United Kingdom it costs the NHS about £2,200 a month as of 2021.^[5] This amount in the United States is about 12,000 USD per month.^[6]

References[edit]

^ "Nintedanib (Ofev) Use During Pregnancy". Drugs.com. 16 September 2019. Archived from the original on 27 January 2021. Retrieved 9 March 2020.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Vargatef EPAR". European Medicines Agency (EMA). 20 January 2020. Archived from the original on 9 August 2020. Retrieved 9 March 2020.
^ "Ofev- nintedanib capsule". DailyMed. Archived from the original on 23 April 2021. Retrieved 22 April 2021.
^ ^a ^b ^c ^d ^e ^f ^g "Nintedanib Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 13 November 2021.
^ ^a ^b ^c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1037. ISBN 978-0857114105.
^ "Ofev Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 August 2021. Retrieved 13 November 2021.

[Drugs.com_pregnancy-1] "Nintedanib (Ofev) Use During Pregnancy". Drugs.com. 16 September 2019. Archived from the original on 27 January 2021. Retrieved 9 March 2020.

[EPAR2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Vargatef EPAR". European Medicines Agency (EMA). 20 January 2020. Archived from the original on 9 August 2020. Retrieved 9 March 2020.

[Ofev_FDA_label-3] "Ofev- nintedanib capsule". DailyMed. Archived from the original on 23 April 2021. Retrieved 22 April 2021.

[AHFS2021-4] ^ ^a ^b ^c ^d ^e ^f ^g "Nintedanib Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 13 November 2021.

[BNF81-5] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1037. ISBN 978-0857114105.

[6] "Ofev Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 August 2021. Retrieved 13 November 2021.

[1]

[2]

[3]

[4]

[5]

[6]